← Back to catalogue
Published

macitentan

vr.tr.macitentan · thing-q6724151

Enable an agent to identify macitentan, assess the suitability of a particular material lot, and recognize the evidence and constraints governing its handling and pharmaceutical use.

Thing Registry Physical world and living systems PHY.MAT

Bundle → Layer → Finding → Questions Filled

6 bundles · 11 layers · 18 findings · 28 questions

Macitentan identity Establish what counts as macitentan and distinguish substance identity from associated medicines.

Molecular recognition

Connect structure and identifiers to evidence from the actual material.

Structure-confirmed parent

Require a structure match supported by appropriate analytical evidence, not merely a supplier name or nominal mass.

  1. Which authoritative structure and identifiers define macitentan for this record? definition
  2. Which reference-standard comparison and orthogonal measurements confirm the sample as macitentan? measurement

Related entity boundaries

Separate the parent substance, metabolites and macitentan-containing products.

Substance, product and metabolite separation

Represent ingredients and metabolic transformations as relationships between distinct entities.

  1. Does the incoming name identify macitentan itself, a formulated product or a related metabolite? boundary
  2. Which evidence establishes the relationship without transferring the other entity's properties to macitentan? provenance
Macitentan material behavior Describe the physical form and conditions that govern usable macitentan material.

Solid form and particles

Establish the observed solid state and particle characteristics of each lot.

Characterized solid material

Tie solid-form assignments to diffraction or thermal evidence and distinguish form changes from particle-size effects.

  1. What measurements establish this lot's solid form, water or solvent content and particle-size distribution? measurement
  2. Which observed differences would require requalification before the intended analytical or pharmaceutical use? action

Dissolution and stability

Record conditions under which macitentan dissolves and retains its measured composition.

Condition-qualified usability

Keep bulk-solid stability, solution stability and finished-product storage evidence separate.

  1. What solubility and precipitation behavior are measured at the intended solvent composition, pH, temperature and concentration? measurement
  2. What evidence supports storage conditions and a usable lifetime for this bulk material or prepared solution? provenance
Macitentan lot quality Determine whether a particular lot meets requirements for its declared use.

Assay and related substances

Quantify parent content and resolve relevant accompanying compounds.

Selective quality measurements

Require methods capable of distinguishing macitentan from relevant related substances and degradation products.

  1. How is macitentan content quantified, and are water, residual solvents and reporting basis accounted for? measurement
  2. Which impurities and degradation products must the method resolve, and what evidence supports their limits? provenance

Traceability and release

Connect sample history and quality evidence to a permitted use.

Use-specific lot disposition

Treat research reagent, reference standard and pharmaceutical ingredient suitability as distinct determinations.

  1. Which manufacturer, lot history, certificate and reference-standard qualification support this material's declared grade? provenance
  2. Does the lot meet the applicable use-specific specification, or must it remain quarantined or undergo retesting? action
Macitentan biological action Relate the parent substance to receptor effects and biologically relevant exposure.

Endothelin receptor pharmacology

Capture receptor-specific evidence with its experimental context.

Contextualized receptor antagonism

Distinguish binding measurements, functional antagonism and downstream biological responses.

  1. What ETA and ETB activity was measured, in which species and assay system, and using which endpoint? measurement
  2. What evidence permits comparison with another endothelin antagonist under matched experimental conditions? boundary

Parent and metabolite exposure

Track metabolism and exposure without collapsing distinct analytes.

Separate exposure and interaction evidence

Associate concentrations and interaction findings with the measured analyte, regimen and study population.

  1. Which measurements separately quantify macitentan and its active metabolite, including sampling times and total or unbound concentration? measurement
  2. How do CYP3A4 or combined CYP3A4/CYP2C9 interactions change exposure, and which current label governs the resulting constraint? action
Macitentan hazards and use constraints Connect macitentan-specific risks to handling decisions and applicable medicinal-product records.

Bulk material exposure

Assess exposure during weighing, transfer, solution preparation and disposal.

Evidence-based handling controls

Establish controls from an applicable SDS and exposure assessment rather than translating a therapeutic dose into a workplace limit.

  1. Which dated SDS and jurisdiction-specific classification apply to this macitentan material and concentration? provenance
  2. What containment, protective measures and waste route follow from the operation's dust, splash and reproductive-exposure assessment? action

Dated pharmaceutical authority

Link the substance to current product-level approvals and use restrictions.

Jurisdiction-specific use boundaries

Version approval scope and safety requirements by jurisdiction and product without making them intrinsic material properties.

  1. Which current approval and label establish the indication, eligible population and restrictions for the linked macitentan product? provenance
  2. Which pregnancy-related, hepatic, hematologic and interaction requirements must the linked clinical workflow check before use? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.

Reported evidence

Findings from the breadth pass, kept separate from the structural claims.

Check these first

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these check these first hold for the sense of macitentan this model covers, and on what evidence? provenance

Identifiers and schemes

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these identifiers and schemes hold for the sense of macitentan this model covers, and on what evidence? provenance

Standards and regulation

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these standards and regulation hold for the sense of macitentan this model covers, and on what evidence? provenance

Real-world use

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these real-world use hold for the sense of macitentan this model covers, and on what evidence? provenance

Typical measurements

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these typical measurements hold for the sense of macitentan this model covers, and on what evidence? provenance

Failure modes and hazards

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these failure modes and hazards hold for the sense of macitentan this model covers, and on what evidence? provenance

Regional variation

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these regional variation hold for the sense of macitentan this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these neighbouring kinds and how to tell them apart hold for the sense of macitentan this model covers, and on what evidence? provenance

Classifiers Filled

Family
Thing Registry
Category
Physical world and living systems
Entry kind
thing
Plane
PHY
Domain
PHY.MAT

What it is Filled

Macitentan is a synthetic small-molecule drug substance that antagonizes endothelin ETA and ETB receptors and is used to treat pulmonary arterial hypertension.

In scope

  • Molecular identity and identifiers distinguishing macitentan from related endothelin receptor antagonists
  • Solid form, particle properties, solubility and condition-dependent stability
  • Lot identity, assay, impurities and fitness for an explicitly stated use
  • Endothelin receptor activity and relationships to active metabolites
  • Substance hazards and links to dated, jurisdiction-specific pharmaceutical requirements

Out of scope

  • Finished tablets, packaging, excipients and brand-specific product specifications
  • Macitentan-tadalafil combination products as complete medicinal products
  • Aprocitentan and other metabolites as independently modeled substances
  • Manufacturing routes, equipment and process operation
  • Individual prescribing decisions, patient records and pulmonary arterial hypertension care pathways

Why it exists Filled

Enable an agent to identify macitentan, assess the suitability of a particular material lot, and recognize the evidence and constraints governing its handling and pharmaceutical use.

Distinguishing features Filled

  • Match a structure-resolved identity to CAS 441798-33-0 and PubChem CID 16004692; a similar name or therapeutic class is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Macitentan)
  • Check for molecular formula C19H20Br2N6O4S and the brominated pyrimidine, ether and N-propylsulfamide connectivity; molecular mass alone cannot establish identity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Macitentan)
  • Distinguish macitentan from its related active metabolite ACT-132577 through explicit molecular structure and analytical separation. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Macitentan)
  • Classify Opsumit tablets and macitentan-containing combinations through a contains-macitentan relationship, rather than treating their brand names as equivalent material identities. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Macitentan)

What robots and AI may and may not do Filled

Must not

  • Recommend it or a dose for a particular patient.
  • Downplay or omit its pregnancy warnings when describing it.
  • Supply it outside lawful pharmaceutical channels and its risk programmes.
  • Present it as a cure for pulmonary arterial hypertension.

Only with a human decision

  • Any decision to start, stop or change a patient's treatment.
  • Releasing or destroying a material lot.

May

  • Identify macitentan by name, identifiers and documented properties, citing sources.
  • Report approved uses and warnings, including those on pregnancy, from official product information.
  • Check a material lot's certificate of analysis against its specification.

Moral aspects Filled

  • Harm to an unborn child is a central risk, so information on contraception and testing must be honest.
  • Specialist drugs are expensive; access is a question of fairness.

Who is affected

  • Patients with pulmonary hypertension
  • Women who may become pregnant
  • Prescribers and pharmacists

Owners Filled

Steward

The marketing authorization holder for each medicine; the national medicines regulator oversees it.

Master systems

  • National medicines registers

Links to other meta-models Filled

parent

  • Q11173 - registry parent class

What else AI and robots need to interact with it Filled

Identity and identifiers required Filled

  • Vercy registry: vr.tr.macitentan
  • Wikidata: Q6724151 (https://www.wikidata.org/wiki/Q6724151)

Direct properties required Filled

  • Chemical identity: Structure identifier, CAS number, PubChem CID and verified synonym
  • Assay and reporting basis: % mass fraction; as-is, dried or solvent-free basis; method and uncertainty
  • Related substances: % or mg/kg for each identified or unidentified impurity, with detection and quantification limits
  • Solid-state identity: Observed crystalline or amorphous state; characterized form; hydrate or solvate status; unknown
  • Solubility profile: mg/mL or mol/L, with solvent, pH, temperature, solid form and equilibration method
  • Thermal behavior: °C with method, heating rate and identification of melting, transition or decomposition
  • Particle-size distribution: µm; D10, D50 and D90 with dispersion and measurement method
  • Endothelin receptor activity: ETA and ETB assay endpoints in nM, with assay system, endpoint and exposure duration
  • Parent-metabolite relationship: Macitentan to identified metabolite, with transformation and evidence
  • Material disposition: Quarantined, released for a stated use, rejected, expired or awaiting retest
  • Applicable hazard and regulatory evidence: Dated SDS, classification authority, jurisdiction, medicinal-product label and approval record

Recognition required Filled

  • Identity rests on the label, batch record and certificate of analysis, not appearance.
  • Packs carry pregnancy warnings required by the regulator.

Capabilities and actions required Filled

  • Reconcile a supplier sample or registry record against macitentan's verified molecular identity.
  • Select identity, assay and impurity measurements appropriate to the material and intended use.
  • Assess whether a lot can be released, requires retesting or should remain quarantined.
  • Determine evidence-supported conditions for analytical dissolution, storage and powder handling.
  • Link receptor and exposure evidence to the correct parent substance or metabolite.
  • Flag applicable hazard and labeling constraints for review by the responsible laboratory or clinical professional.

Hazards and failure modes required Filled

  • Harm to an unborn child if taken during pregnancy.
  • Liver effects and falling blood counts need monitoring.
  • Exposure of pregnant staff during manufacture or handling.

Standards and interfaces required Filled

  • ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, International Council for Harmonisation.

Context of use required Filled

  • Macitentan is encountered as a pharmaceutical substance in medicine manufacture, analytical testing and research on endothelin receptors.
  • Its therapeutic use concerns pulmonary arterial hypertension, while material assessment requires evidence of chemical identity, purity and formulation.

Sources Filled

  1. Wikidata item Q6724151: macitentan - identity and sense of the item
  2. Wikipedia: Macitentan - general description of the item

Open questions

  • Which authoritative EC and jurisdiction-specific substance identifiers should accompany the verified CAS and PubChem identities?
  • Which macitentan solid forms are experimentally established, and what evidence determines whether their differences affect intended use?
  • What reliable measurements establish pH-dependent solubility, thermal transitions and decomposition behavior for characterized material?
  • Which current compendial or approved specifications govern macitentan assay, related substances, residual solvents and retest periods for each intended grade?
  • What authoritative bulk-material GHS classifications, occupational exposure limits or exposure bands, and environmental disposal requirements apply in the target jurisdiction?

Machine files

Provenance

thing registry research (pass 2) · unreviewed

Built from: models/things/publications/thing-q6724151/spec.json